Trial reportJournal of Parkinson's disease2016
Subthalamic Nucleus Deep Brain Stimulation May Reduce Medication Costs in Early Stage Parkinson's Disease.
Trial report in Journal of Parkinson's disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Devices for remote continuous monitoring of people with Parkinson's disease: a systematic review and cost-effectiveness analysis.Health technology assessment (Winchester, England) · 2024Pooled it
- Cost Effectiveness of Deep Brain Stimulation for Parkinson's Disease: A Systematic Review.Applied health economics and health policy · 2024Pooled it
- Early subthalamic nucleus deep brain stimulation in Parkinson's disease reduces long-term medication costs.Clinical neurology and neurosurgery · 2021Trial
- Trial
- Effects of deep brain stimulation on rest tremor progression in early stage Parkinson disease.Neurology · 2018Trial
- Effects of deep brain stimulation on functional autonomy and quality of life in Parkinson's disease: A systematic review and meta-analysis.Journal of Parkinson's disease · 2026Review
- N2GNet tracks gait performance from subthalamic neural signals in Parkinson's disease.NPJ digital medicine · 2025Article
- N2GNet tracks gait performance from subthalamic neural signals in Parkinson's disease.Research square · 2024Article
- Eleven-Year Outcomes of Deep Brain Stimulation in Early-Stage Parkinson Disease.Neuromodulation : journal of the International Neuromodulation Society · 2023Article
- BDNF rs6265 Genotype Influences Outcomes of Pharmacotherapy and Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease.Neuromodulation : journal of the International Neuromodulation Society · 2022Article
- Neurologists' Attitudes Toward Use and Timing of Deep Brain Stimulation.Neurology. Clinical practice · 2021Article
- Capturing Initial Understanding and Impressions of Surgical Therapy for Parkinson's Disease.Frontiers in neurology · 2021Article
- Unraveling the Role of Astrocytes in Subthalamic Nucleus Deep Brain Stimulation in a Parkinson's Disease Rat Model.Cellular and molecular neurobiology · 2020Article
- Longitudinal medication profile and cost savings in Parkinson's disease patients after bilateral subthalamic nucleus deep brain stimulation.Journal of neurology · 2020Article
- Perspectives on Deep Brain Stimulation and Its Earlier Use for Parkinson's Disease: A Qualitative Study of US Patients.Brain sciences · 2020Article
- Will deep brain stimulation increase the incidence of induced psychosis? Post-operation follow-ups for 1 hundred patients from 2004-2017.BioMedicine · 2018Article
- Earlier Intervention with Deep Brain Stimulation for Parkinson's Disease.Parkinson's disease · 2017Review
- Comparison of Globus Pallidus Interna and Subthalamic Nucleus in Deep Brain Stimulation for Parkinson Disease: An Institutional Experience and Review.Parkinson's disease · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundSubthalamic nucleus deep brain stimulation (STN-DBS) is well-known to reduce medication burden in advanced stage Parkinson's disease (PD). Preliminary data from a prospective, single blind, controlled pilot trial demonstrated that early stage PD subjects treated with STN-DBS also required less medication than those treated with optimal drug therapy (ODT).
objectiveThe purpose of this study was to analyze medication cost and utilization from the pilot trial of DBS in early stage PD and to project 10 year medication costs.
methodsMedication data collected at each visit were used to calculate medication costs. Medications were converted to levodopa equivalent daily dose, categorized by medication class, and compared. Medication costs were projected to advanced stage PD, the time when a typical patient may be offered DBS.
resultsMedication costs increased 72% in the ODT group and decreased 16% in the DBS+ODT group from baseline to 24 months. This cost difference translates into a cumulative savings for the DBS+ODT group of $7,150 over the study period. Projected medication cost savings over 10 years reach $64,590. Additionally, DBS+ODT subjects were 80% less likely to require polypharmacy compared with ODT subjects at 24 months (p < 0.05; OR = 0.2; 95% CI: 0.04-0.97).
conclusionsSTN-DBS in early PD reduced medication cost over the two-year study period. DBS may offer substantial long-term reduction in medication cost by maintaining a simplified, low dose medication regimen. Further study is needed to confirm these findings, and the FDA has approved a pivotal, multicenter clinical trial evaluating STN-DBS in early PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.